Advertisement
Advertisement

Indicator

Free Access

Pay per View

Partial Free Access

Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 2 29 87 63
Fax: +49 (0)711 - 2 29 87 65
send an Email


Archive

Deep-vein thrombosis: A United States cost model for a preventable and costly adverse event

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
DOI: http://dx.doi.org/10.1160/TH11-02-0132
Issue: 2011: 106/3 (Sep) pp. 389–565
Pages: 405-415

Deep-vein thrombosis: A United States cost model for a preventable and costly adverse event

C. E. Mahan (1), M. T. Holdsworth (1), S. M. Welch (2), M. Borrego (1), A. C. Spyropoulos (3)

(1) University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA; (2) Cardinal Health Pharmacy Solutions, Lovelace Medical Center, Albuquerque, New Mexico, USA; (3) Department of Medicine, McMaster University, Hamilton, Ontario, Canada

Summary

Preventable venous thromboembolism (VTE) and “appropriate” type, dose, and duration of prophylaxis are emerging concepts. Contemporary definitions by key quality organisations, including the World Health Organization, have shifted towards “preventable” VTE being considered an adverse event or adverse drug event. A decision tree and cost model were developed to estimate the United States health care costs for total deep-vein thrombosis (DVT), total hospital-acquired DVT, and total “preventable” DVT. Annual cost ranges were obtained in 2010 US dollars for total ($7.5 to $39.5 billion), hospital-acquired ($5 to $26.5 billion), and preventable ($2.5 to $19.5 billion) DVT costs. When the sensitivity analysis was applied – taking into consideration higher incidence rates and costs – annual US total, hospital-acquired, and “preventable” DVT costs ranged from $9.8 to $52 billion, $6.8 to $36 billion, and $3.4 to $27 billion, respectively.

Keywords

Deep-vein thrombosis, Adverse event, Adverse drug event, cost model, preventable

DOI

http://dx.doi.org/10.1160/TH11-02-0132

You may also be interested in...

1.

C. E. Mahan (1), M. E. Borrego (2), A. L. Woersching (2), R. Federici (3), R. Downey (3), J. Tiongson (3), M. C. Bieniarz (3), B. J. Cavanaugh (3), A. C. Spyropoulos (4)

Thromb Haemost 2012 108 2: 291-302

http://dx.doi.org/10.1160/TH12-03-0162

2.

W. Blättler 1 , H. E. Gerlach2

Phlebologie 2005 34 3: 146-156

3.

Alexander T. Cohen1, Giancarlo Agnelli2, Frederick A. Anderson3, Juan I. Arcelus4, David Bergqvist5, Josef G. Brecht6, Ian A. Greer7, John A. Heit8, Julia L. Hutchinson9, Ajay K. Kakkar10, Dominique Mottier11, Emmanuel Oger11, Meyer-Michel Samama12, Michael Spannagl13 for the VTE Impact Assessment Group in Europe (VITAE)

Thromb Haemost 2007 98 4: 756-764

http://dx.doi.org/10.1160/TH07-03-0212